Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 12/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 12/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.77 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831728 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL19632954 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL45924 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL2785531 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL13171965 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL29265327 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL2785024 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL3831721 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL16445250 | 0.97 | OPRD1 (0.93) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 | |
| SCHEMBL19181060 | 0.97 | OPRD1 (0.93) | OPRD1OPRM1OPRK1CYP2D6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099456-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | Progenics Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2009067275-A1 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC (US) | 2009-05-28 | — | — | WO | claimed |
| WO-2008070462-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | claimed |
| US-20210196703-A1 | COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONISTS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-07-01 | — | — | US | disclosed |
| US-20200383970-A1 | Morphinan Derivatives with High Oral Bioavailability | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-20200345718-A1 | Morphinan Derivatives for the Treatment of Drug Overdose | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-05 | — | — | US | disclosed |
| US-10806731-B2 | Compositions of buprenorphine and μ antagonists | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-20 | — | — | US | disclosed |
| EP-2790702-B1 | COMPOSITIONS OF BUPRENORPHINE AND MU-OPIOID RECEPTOR ANTAGONISTS | ALKERMES PHARMA IRELAND LTD (IE) | 2020-04-01 | — | — | EP | disclosed |
| EP-3569234-A1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF DRUG OVERDOSE | Alkermes Pharma Ireland Limited (IE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190247387-A1 | Compositions of Buprenorphine and µ Antagonists | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-08-15 | — | — | US | disclosed |
| US-10188643-B2 | Compositions of buprenorphine and μ antagonists | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-01-29 | — | — | US | disclosed |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009067275-A1 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009023567-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023567-A1 | QUATERNARY OPIOID CARBOXAMIDES | RENSSELAER POLYTECHNIC INSTITUTE (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2008070462-A2 | N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS | PROGENICS PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20070099947-A1 | Methods and compositions for the treatment of brain reward system disorders by combination therapy | ALKERMES, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099947-A1 | Methods and compositions for the treatment of brain reward system disorders by combination therapy | ALKERMES, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806731-B2 | Compositions of buprenorphine and μ antagonists | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885OPRK1 4/4885 |
| US-20070099947-A1 | Methods and compositions for the treatment of brain reward system disorders by combination therapy | GRIN2B, OPRK1, GRIN3B | OPRD1 8/4885OPRM1 6/4885OPRK1 2/4885 |
| US-20190247387-A1 | Compositions of Buprenorphine and µ Antagonists | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20090197905-A1 | QUATERNARY OPIOID CARBOXAMIDES | OPRK1, OPRM1, OPRD1 | OPRD1 3/4885OPRM1 2/4885OPRK1 1/4885 |
| US-20200383970-A1 | Morphinan Derivatives with High Oral Bioavailability | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885OPRK1 3/4885 |
| US-10188643-B2 | Compositions of buprenorphine and μ antagonists | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885OPRK1 4/4885 |
| US-20210196703-A1 | COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONISTS | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885OPRK1 4/4885 |
| US-20200345718-A1 | Morphinan Derivatives for the Treatment of Drug Overdose | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.